Will 2018 become known as the year when new cell and gene
therapies began taking hold in the market? While their life-saving
potential is clear in many instances (based on clinical evidence
available at launch), there are many medical and technological
uncertainties that long-term data and further research likely will
address. The more fundamental question of who pays for therapies
at a price that is financially attractive to industry and financially
affordable for the buyer is harder to answer. How can the market
set a fair price for drugs that addresses the sustainability of the
research industry and the needs of healthcare systems and
patients? Too high a price means healthcare systems and patients
are unable to afford a drug, thereby denying patients access to
life-saving medicines. At too low a price, the research industry, as
we know it, could flounder. In this study, we assess the perceived
impact of price on the sustainability and long-term viability of the
industry behind the emerging innovative and potentially curative
interventions along with associated negotiated rebates.
Navigating payer challenges in rare disease
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences...